Portable MRI developer Hyperfine has enrolled the first patients in a trial to test its Swoop system in Alzheimer’s disease patients undergoing amyloid-targeting therapy.
The CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study is designed to assess the clinical utility and workflow benefits of Swoop system. Imaging will be performed at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIAs) in Alzheimer’s patients.
The study is led by Tammie Benzinger, MD, PhD, a professor of radiology and chief of MRI service at the Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, MO.
